Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis

Uchikura, Keiichiro; Takao, Sonshin; Nakajo, Akihiro; Miyazono, Futoshi; Nakashima, Saburo; Tokuda, Kouki; Matsumoto, Masataka; Shinchi, Hiroyuki; Natsugoe, Shoji; Aikou, Takashi

doi:10.1007/bf02573871

Cited by 48 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another early study by Uchikura et al looked at CEA mRNA in 67 patients undergoing pancreatic surgery [49]. They looked at preoperative and intraoperative CEA mRNA from peripheral, central and portal venous blood intraoperatively via nested RT-PCR with no enrichment technique.…”

Section: Studies Of Ctcs In Pancreatic Cancermentioning

confidence: 99%

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Court

Ankeny

Hou

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the fourth most common cause of cancer-related death in the USA, primarily due to late presentation coupled with an aggressive biology. The lack of adequate biomarkers for diagnosis and staging confound clinical decision-making and delay potentially effective therapies. Circulating tumor cells (CTCs) are a promising new biomarker in PC. Preliminary studies have demonstrated their potential clinical utility, and newer CTC isolation platforms have the potential to provide clinicians access to tumor tissue in a reliable, real-time manner. Such a ‘liquid biopsy’ has been demonstrated in several cancers, and small studies have demonstrated its potential applications in PC. This article reviews the available literature on CTCs as a biomarker in PC and presents the latest innovations in CTC research as well as their potential applications in PC.

show abstract

Section: Studies Of Ctcs In Pancreatic Cancermentioning

confidence: 99%

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Court

Ankeny

Hou

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…[73] In a prospective study of 140 patients undergoing EUS, the luminal fluid that is routinely aspirated through the accessory channel was submitted for cytological analysis. Luminal fluid cytology was positive for malignancy in 48% of patients with a luminal cancer, which may be expected given the inherent tumor shedding that occurs within the GI lumen.…”

Section: Miscellaneous Adverse Eventsmentioning

confidence: 99%

Basic techniques in endoscopic ultrasound-guided fine needle aspiration for solid lesions: Adverse events and avoiding them

Fujii

Levy

2014

Endosc Ultrasound

View full text Add to dashboard Cite

Endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) is often the preferred technique for tissue acquisition in the diagnosis of suspected intrathoracic and intraabdominal pathology. Although EUS FNA is a safe and accurate procedure, it has been associated with a low risk of adverse events. The unique properties of the echoendoscope and its ability to acquire tissue outside of the gastrointestinal lumen impart risks that are not associated with routine endoscopic procedures. In this review, we discuss the risk of perforation related to the echoendoscope itself and adverse events related to FNA of solid masses including infections, bleeding, pancreatitis and pancreatic duct leak, bile duct leak and tumor seeding. We also provide tips on how to avoid the most common adverse events related to EUS-FNA.

show abstract

“…Intraoperative measurement of CEA mRNA in venous blood by RT-PCR has shown prognostic value in detecting disease recurrence, especially in patients with high-stage disease [39, 40]. Mataki et al investigated the significance of CTCs in the blood as an early indicator of PDA recurrence following curative resection [13].…”

Section: Discussionmentioning

confidence: 99%

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Osayi

Bloomston

Schmidt

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

show abstract

Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis

Abstract: Intraoperative molecular detection of circulating tumor cells in patients with biliary-pancreatic cancer relates to a high risk of hematogenous metastasis and is associated with unfavorable prognosis even after curative resection.

Cited by 48 publications

References 22 publications

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Basic techniques in endoscopic ultrasound-guided fine needle aspiration for solid lesions: Adverse events and avoiding them

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Contact Info

Product

Resources

About